Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains relatively well preserved, GA often causes considerable compromise of visual function and quality of life. No treatment currently exists. We evaluated the safety and efficacy of pegcetacoplan, a complement C3 inhibitor, for treatment of GA. DESIGN: Prospective, multicenter, randomized, sham-controlled phase 2 study. PARTICIPANTS: Two hundred forty-six patients with GA. METHODS: Patients with GA were assigned randomly in a 2:2:1:1 ratio to receive intravitreal injections of 15 mg pegcetacoplan monthly or every other month (EOM) or sham intravitreal injections monthly or EOM for 12 months with follow-up at months 15 and 18. Area and growth of GA were measured using fundus autofluorescence imaging. MAIN OUTCOME MEASURES: The primary efficacy end point was mean change in square root GA lesion area from baseline to month 12. Secondary outcome measures included mean change from baseline in GA lesion area without the square root transformation, distance of GA lesion from the fovea, best-corrected visual acuity (BCVA), low-luminance BCVA, and low-luminance visual acuity deficit. The primary safety end point was the number and severity of treatment-emergent adverse events. RESULTS: In patients receiving pegcetacoplan monthly or EOM, the GA growth rate was reduced by 29% (95% confidence interval [CI], 9-49; P = 0.008) and 20% (95% CI, 0-40; P = 0.067) compared with the sham treatment group. Post hoc analysis showed that the effect was greater in the second 6 months of treatment, with observed reductions of 45% (P = 0.0004) and 33% (P = 0.009) for pegcetacoplan monthly and EOM, respectively. Two cases of culture-positive endophthalmitis and 1 case of culture-negative endophthalmitis occurred in the pegcetacoplan monthly group. New-onset investigator-determined exudative AMD was reported more frequently in pegcetacoplan-treated eyes (18/86 eyes [20.9%] and 7/79 eyes [8.9%] in monthly and EOM groups, respectively) than in sham-treated eyes (1/81 eyes [1.2%]). CONCLUSIONS: Local C3 inhibition with pegcetacoplan resulted in statistically significant reductions in the growth of GA compared with sham treatment. Phase 3 studies will define the efficacy and safety profile further.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flaxman, S. R., Bourne, R. R. A., Resnikoff, S., Ackland, P., Braithwaite, T., Cicinelli, M. V., Das, A., Jonas, J. B., Keeffe, J., Kempen, J. H., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30393-5 · Cited by 3,477
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Fritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., Burdon, K. P., Hebbring, S. J., Wen, C., Gorski, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3448 · Cited by 1,544
Self-citationA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
Self-citationMicroglial Phagocytosis of Live Neurons
Brown, G. C., & Neher, J. J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3710 · Cited by 853
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829 · cited 11×
“Genetic variants of complement C3dthe central component of all 3 complement activation pathwaysdand variants of CFH, CFI, and CFBdfactors that affect C3 activation or degradation of its active fragmentsdare associated strongly with increased risk of both the exudative and atrophic forms of AMD.(12,13) Complement activ…”
BackgroundInfluentialMonocyte and Macrophage Plasticity in Tissue Repair and Regeneration
Das, A., Sinha, M., Datta, S., Abas, M., Chaffee, S., Sen, C. K., & Roy, S. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.06.001 · Cited by 743
Anderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
Oxidative damage-induced inflammation initiates age-related macular degeneration
Hollyfield, J. G., Bonilha, V. L., Rayborn, M. E., Yang, X., Shadrach, K. G., Lu, L., Ufret, R. L., Salomon, R. G., & Perez, V. L. (2008) · Nature Medicine · doi:10.1038/nm1709 · Cited by 710
Tarique, A. A., Logan, J., Thomas, E., Holt, P. G., Sly, P. D., & Fantino, E. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0012oc · Cited by 587
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402
Systemic Complement Activation in Age-Related Macular Degeneration
Scholl, H. P. N., Issa, P. C., Walier, M., Janzer, S., Pollok-Kopp, B., Börncke, F., Fritsche, L. G., Chong, N. V., Fimmers, R., Wienker, T., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002593 · Cited by 363
Self-citationHolz, F. G., Sadda, S. R., Busbee, B., Chew, E. Y., Mitchell, P., Tufail, A., Brittain, C., Ferrara, D., Gray, S., Honigberg, L., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1544 · Cited by 354
Complement — tapping into new sites and effector systems
Kolev, M., Friec, G. L., & Kemper, C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3761 · Cited by 349
Sunness, J. S., Gonzalez-Baron, J., Applegate, C. A., Bressler, N. M., Tian, Y., Hawkins, B., Barron, Y., & Bergman, A. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90340-8 · Cited by 348
Gu, X., Meer, S. G., Miyagi, M., Rayborn, M. E., Hollyfield, J. G., Crabb, J. W., & Salomon, R. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305460200 · Cited by 325
Sunness, J. S., Rubin, G. S., Applegate, C. A., Bressler, N. M., Marsh, M. J., Hawkins, B. S., & Haselwood, D. (1997) · Ophthalmology · doi:10.1016/s0161-6420(97)30079-7 · Cited by 309
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Self-citationYehoshua, Z., Rosenfeld, P. J., Gregori, G., Feuer, W. J., Falcão, M., Lujan, B. J., & Puliafito, C. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.08.018 · Cited by 292
Self-citationEcosystem Overfishing in the Ocean
Coll, M., Libralato, S., Tudela, S., Palomera, I., & Pranovi, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003881 · Cited by 288
Change in Area of Geographic Atrophy in the Age-Related Eye Disease Study: AREDS Report Number 26
(2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.198 · Cited by 276
FRIEDMAN, B. (1941) · Archives of Ophthalmology · doi:10.1001/archopht.1941.00870100042005 · Cited by 260
Chang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 239
Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction
Coffey, P. J., Gias, C., McDermott, C. J., Lundh, P., Pickering, M. C., Sethi, C., Bird, A., Fitzke, F. W., Maass, A., Chen, L. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705079104 · Cited by 231
Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.012 · Cited by 214 · cited 1×
“Although neovascular AMD usually can be treated effectively with vascular endothelial growth factor (VEGF) inhibitors, patients frequently demonstrate GA within 5 years of starting therapy.(10) There are no approved treatments for GA.”
BackgroundMacrophage polarization in the maculae of age‐related macular degeneration: A pilot study
Cao, X., Shen, D., Patel, M. M., Tuo, J., Johnson, T. M., Olsen, T. W., & Chan, C. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02695.x · Cited by 209
Hill, A., Rother, R. P., Arnold, L., Kelly, R., Cullen, M. J., Richards, S. J., & Hillmen, P. (2010) · Haematologica · doi:10.3324/haematol.2009.007229 · Cited by 197
Feuer, W. J., Yehoshua, Z., Gregori, G., Penha, F. M., Chew, E. Y., Ferris, F. L., Clemons, T. E., Lindblad, A. S., & Rosenfeld, P. J. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.572 · Cited by 183
Self-citationLanger, H. F., Chung, K.-J., Orlova, V. V., Choi, E. Y., Kaul, S., Kruhlak, M. J., Alatsatianos, M., DeAngelis, R. A., Roche, P. A., Magotti, P., et al. (2010) · Blood · doi:10.1182/blood-2010-01-261503 · Cited by 176 · cited 2×
“These cells have been classified broadly into 3 categories: (1) resting M0; (2) proinflammatory, prophagocytic M1; and (3) reparative, proangiogenic M2 phenotypes, but exhibit high phenotypic plasticity in response to changes in their local microenvironment.43,44 An analysis of macrophage polarization in postmortem ey…”
BackgroundVision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye
Bressler, N. M., Chang, T. S., Suñer, I. J., Fine, J. T., Dolan, C., Ward, J., & Ianchulev, T. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.09.002 · Cited by 150
Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Rosenfeld, P. J., Dugel, P. U., Holz, F. G., Heier, J. S., Pearlman, J. A., Novack, R. L., Csaky, K. G., Koester, J. M., Gregory, J. K., & Kubota, R. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.03.059 · Cited by 132
Self-citationvan der Schaft, T. L., Mooy, C. M., de Bruijn, W. C., & de Jong, P. T. (1993) · British Journal of Ophthalmology · doi:10.1136/bjo.77.10.657 · Cited by 126
Chakravarthy, U., Bailey, C. C., Johnston, R. L., McKibbin, M., Khan, R. S., Mahmood, S., Downey, L., Dhingra, N., Brand, C., Brittain, C. J., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.036 · Cited by 118
McLeod, D. S., Bhutto, I., Edwards, M. M., Silver, R. E., Seddon, J. M., & Lutty, G. A. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-20049 · Cited by 106
Maguire, M. G., Daniel, E., Shah, A. R., Grunwald, J. E., Hagstrom, S. A., Avery, R. L., Huang, J., Martin, R. W., Roth, D. B., Castellarin, A. A., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.017 · Cited by 93
Grassmann, F., Fleckenstein, M., Chew, E. Y., Strunz, T., Schmitz-Valckenberg, S., Göbel, A. P., Klein, M. L., Ratnapriya, R., Swaroop, A., Holz, F. G., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126636 · Cited by 88
Self-citationRosenfeld, P. J., Berger, B. B., Reichel, E., Danis, R. P., Gress, A., Ye, L., Magee, M. H., Parham, L. R., & McLaughlin, M. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.03.001 · Cited by 83
Self-citationRuan, C.-C., Ge, Q., Li, Y., Li, X.-D., Chen, D.-R., Ji, K.-D., Wu, Y.-J., Sheng, L.-J., Yan, C., Zhu, D.-L., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304927 · Cited by 76
Katschke, K. J., Xi, H., Cox, C., Truong, T., Malato, Y., Lee, W. P., McKenzie, B., Arceo, R., Tao, J., Rangell, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25557-8 · Cited by 75
Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review
Kaszubski, P. A., Ami, T. B., Saade, C., & Smith, R. T. (2016) · Ophthalmic Research · doi:10.1159/000443209 · Cited by 68
Joseph, K., Kulik, L., Coughlin, B., Kunchithapautham, K., Bandyopadhyay, M., Thiel, S., Thielens, N. M., Holers, V. M., & Rohrer, B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421891 · Cited by 65
Synthesis and Propagation of Complement C3 by Microglia/Monocytes in the Aging Retina
Rutar, M., Valter, K., Natoli, R., & Provis, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093343 · Cited by 56
Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury
Sweigard, J. H., Matsumoto, H., Smith, K. E., Kim, L. A., Paschalis, E. I., Okonuki, Y., Castillejos, A., Kataoka, K., Hasegawa, E., Yanai, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1482 · Cited by 48
Retinal pigment epithelial cells mitigate the effects of complement attack by endocytosis of C5b-9
Georgiannakis, A., Burgoyne, T., Lueck, K., Futter, C., Greenwood, J., & Moss, S. E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500937 · Cited by 41 · cited 1×
“Consistent with this hypothesis, in vitro studies have demonstrated that retinal pigment epithelium cells can use endocytosis as a strategy to prevent accumulation of complement components at the cell surface.(42) By inhibiting C3 activation, pegcetacoplan would prevent further C3 deposition, allowing cells to avoid p…”
BackgroundCorrection: Systemic Complement Activation in Age-Related Macular Degeneration
Scholl, H. P. N., Charbel Issa, P., Walier, M., Janzer, S., Pollok-Kopp, B., Börncke, F., Fritsche, L. G., Chong, N. V., Fimmers, R., Wienker, T., et al. (2008) · PLoS ONE · doi:10.1371/annotation/32b9bc31-ed6d-4d31-9ce0-480407017bad · Cited by 39
Self-citationSaade, C., Ganti, B., Marmor, M. F., Freund, K. B., & Smith, R. T. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305005 · Cited by 23
Ocular Risk Factors for Exudative AMD: A Novel Semiautomated Grading System
Marques, J. P., Costa, M. A., Melo, P., Oliveira, C. M., Pires, I., Cachulo, M. L., Figueira, J., & da Silva, R. M. (2013) · ISRN Ophthalmology · doi:10.1155/2013/464218 · Cited by 18
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Heier, J. S., Lad, E. M., Holz, F. G., Rosenfeld, P. J., Guymer, R. H., Boyer, D., Grossi, F., Baumal, C. R., Korobelnik, J.-F., Slakter, J. S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01520-9 · Cited by 520
Self-citationAge-related macular degeneration
Guymer, R. H., & Campbell, T. G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02609-5 · Cited by 502
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., Joondeph, B. C., Randolph, J., Masonson, H., & Rezaei, K. A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.027 · Cited by 469
Metadata
- Authors
- Liao, D. S., Grossi, F. V., El Mehdi, D., Gerber, M. R., Brown, D. M., Heier, J. S., Wykoff, C. C., Singerman, L. J., Abraham, P., Grassmann, F., Nuernberg, P., Weber, B. H. F., Deschatelets, P., Kim, R. Y., Chung, C. Y., Ribeiro, R. M., Hamdani, M., Rosenfeld, P. J., Boyer, D. S., Slakter, J. S., & Francois, C. G.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 127
- Issue
- 2
- Pages
- 186-195
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2959393635
- Cited by
- 519
- References
- 49
- FWCI
- 38.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.